|
|
|
| Age (years) |
28.9 ± 4.8 |
| Gender |
|
| Male (M) |
6 |
| Female (F) |
9 |
| Body Surface Area (m2) |
1.56 ± 0.1 |
| Deferoxamine dose (mg/kg) |
38 ± 10.2 |
| 5.3 days/week |
|
| CMR measures: |
|
| Myocardial T2* (ms) [>20] |
5.7 ± 1.0 |
| Liver T2* (ms) [>19] |
3.7 ± 2.9 |
| LV end diastolic volume index (mL/m2) [M:45–152, F:54–121] |
87.1 ± 31.6 |
| LV end systolic volume index (mL/m2) [M:13–34, F:6–35] |
44.4 ± 24.9 |
| LV ejection fraction (%) [M > 59%; F > 63%] |
51.2 ± 10.9 |
| Blood measures: |
|
| Transfusional red blood cell input (mL/kg/year) |
155.1 ± 40.9 |
| Mean year hemoglobin (g/dL) |
11.0 ± 1.2 |
| Hepatitis C positive |
|
| Yes |
14 |
| No |
1 |
| Biochemistry |
|
| Serum ferritin (μg/L) [M: 5–104, F: 4–254 ] |
2057 ± 7.6 |
| Alanine aminotransferase (IU/L) [5-35] |
53.4 ± 34.8 |
| BNP (pmol/L) [<100] |
26.0 (9.8–758) |
| Serum creatinine (mg/dL) [0.6–1.2] |
0.68 ± 0.19 |
Tanner et al. Journal of Cardiovascular Magnetic Resonance 2008 10:12 doi:10.1186/1532-429X-10-12 |
|